Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OctoPlus has signed a feasibility agreement with a pharmaceutical company based in US to develop a controlled release formulation of the client's therapeutic compound for local delivery into joints.
Subscribe to our email newsletter
The financial terms of the current agreement have not been disclosed.
The contract covers initial activities in developing a controlled release formulation of an undisclosed compound using the drug delivery technology PolyActive, the company said.
The project is expected to progress into a full development, manufacturing and licensing agreement, if the evaluation is successful.
OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on their proprietary drug delivery technologies.